Neurocrine Biosciences Highlights Neuroscience Commitment at September 2025 Investor Conferences
- Neurocrine Biosciences will participate in four key investor conferences in September 2025 to showcase its commitment to neuroscience.
- Leadership will discuss advancements in clinical pipelines targeting neurological disorders, including tardive dyskinesia and Huntington's disease.
- The company emphasizes its dedication to innovative therapies and fostering relationships within the healthcare community during these engagements.
Neurocrine Biosciences Showcases Commitment to Neuroscience at Upcoming Conferences
Neurocrine Biosciences, Inc., a leader in the biopharmaceutical industry focusing on neurological and neuropsychiatric disorders, is set to participate in four key investor conferences in September 2025. This strategic involvement underlines the company’s commitment to transparency and engagement with stakeholders as it continues to advance its innovative treatment portfolio. Chief Financial Officer Matt Abernethy, Chief Commercial Officer Eric Benevich, and Vice-President of Investor Relations Todd Tushla will present at the Cantor Global Healthcare Conference on September 3, highlighting Neurocrine's ongoing initiatives in the neuroscience sector.
The company's leadership, including Chief Executive Officer Kyle Gano and Chief Medical Officer Sanjay Keswani, will further represent Neurocrine at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9. This platform offers an opportunity to discuss the latest developments in Neurocrine's clinical pipeline, which aims to address complex neurological conditions, including tardive dyskinesia and chorea associated with Huntington's disease. Following this, Gano, Keswani, and Tushla will engage with investors at the Baird 2025 Global Healthcare Conference on September 10, reinforcing the company's position as a frontrunner in neurotherapeutics.
In addition to these conferences, Gano and Tushla will present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry and Epilepsy Virtual Summit on September 17. Neurocrine’s participation in these events reflects its strategic focus on fostering relationships within the healthcare community and ensuring that its advancements in treating neuroendocrine and neuropsychiatric disorders are well-communicated. Live webcasts of these presentations will be available on Neurocrine's website, allowing wider access to the information and insights shared during these significant engagements.
Beyond its conference appearances, Neurocrine Biosciences boasts an impressive array of FDA-approved therapies and a robust clinical pipeline, emphasizing its dedication to addressing challenging health conditions. With over three decades of experience, the company remains committed to alleviating patient suffering through innovative scientific approaches. As Neurocrine continues to expand its capabilities, it positions itself as a vital player in the evolving landscape of neuroscience and biopharmaceuticals. For more information, interested parties can visit the company's website or follow its updates on social media platforms.
